Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial

Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial

We conducted a clinical trial to assess the safety and putative efficacy of an additional human rabies immune globulin (HRIG; KEDRAB) versus an older product (Comparator, HyperRAB S/D® [Grifols]) and determine whether HRIG interferes with development of endogenous antibodies versus Comparator, when...

Full description

Bibliographic Details
Main Authors: Mark A. Matson, Eran Schenker, Michal Stein, Vladislava Zamfirova, Huy-Binh Nguyen, Garrett E. Bergman
Format: Article
Language:English
Published: Taylor & Francis Group 2020-02-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
immunoglobulin
post-exposure prophylaxis
rabies
vaccine
zoonotic disease
Online Access:http://dx.doi.org/10.1080/21645515.2019.1656967

Internet

http://dx.doi.org/10.1080/21645515.2019.1656967

Similar Items